Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

Hematology. American Society of Hematology. Education Program - 1 Jan 2009

Hughes Timothy P, Branford Susan

Abstract excerpt

The remarkable progress made in the treatment of chronic myeloid leukemia (CML) over the past decade has been accompanied by steady improvements in our capacity to accurately and sensitively monitor response to therapy. After the initial target of therapy, complete cytogenetic response (CCR), is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Examination
Share to Computer Systems
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukocyte Count

Share to Patient Compliance

Share to Remission Induction

Share to RNA, Neoplasm

Source

Identifiers

PMID: 20008233
DOI: 10.1182/asheducation-2009.1.477

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20008233-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.PMID 20008233Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Molecular monitoring in CML and the prospects for treatment-free remissions.Semantic proximity Read ↗

Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response MonitoringSemantic proximity Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Semantic proximity Read ↗

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.Semantic proximity Read ↗

Molecular monitoring in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.Semantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.